Professor Luke Selth

Lab webpage: Prostate Cancer Research Group

Google Scholar: https://scholar.google.com.au/citations?user=IfXWSaQAAAAJ&hl=en

ORCID: https://orcid.org/0000-0002-4686-1418

Luke Selth is Head of the Prostate Cancer Research within the Flinders Health and Medical Research Institute (FHMRI), a Matthew Flinders Professor of Cancer Biology, and Co-Director of FHMRI's Cancer Impact program.

Selth’s research is focussed on prostate cancer, an extremely common disease and a major cause of cancer-related death in men. He has established an internationally-recognised research program focused on understanding and targeting androgen receptor signalling in prostate cancer, investigating cancer cell plasticity and how it leads to therapy resistance, and testing the efficacy of novel drugs for prostate cancer.

Selth is a member of the Research Advisory Committee of the Prostate Cancer Foundation of Australia, the Scientific Advisory Committee for the South Australian Genomics Centre, and the Management Committee of the Freemasons Centre for Male Health and Wellbeing. He has received prestigious fellowships from the European Molecular Biology Organization, Prostate Cancer Foundation of Australia and Prostate Cancer Foundation (US), as well as funding from NHMRC, Cancer Australia, Cancer Council SA, Cancer Council NSW, the Flinders Foundation, Movember and The Hospital Research Foundation. He is an Editorial Board member of Endocrine-Related Cancer, the flagship cancer journal for the Society of Endocrinology, and Cancer Research Communications, the open access journal of the American Association for Cancer Research. His team’s research is regularly published in prominent journals including recent papers in Cancer Research, European Urology, Science Translational Medicine, Nature Cell Biology, Nature Medicine, EMBO Journal, Oncogene, and Nucleic Acids Research.